Thursday, May 9, 2013
Publication and contact
Cell culture and mouse
studies identified androgen receptor antagonists that could help treat
prostate cancers that acquire resistance to Xtandi enzalutamide.
Structural modeling and in vitro mutagenesis assays identified F876L
as a mutation in the androgen receptor that prevents antagonism by Xtandi and
instead causes the drug to behave as a partial agonist. A series of compounds
with D-ring substitutions to the enzalutamide scaffold were synthesized and
shown to inhibit the F876L mutant androgen receptor. In mouse xenograft
models for prostate cancer and in cell lines, the lead D-ring-substituted
compound inhibited growth of F876L mutant prostate cancers, whereas
enzalutamide did not. Next steps include evaluating the lead compound in
additional mouse xenograft models for prostate cancer and determining the
clinical relevance of the mutation.
Medivation Inc. and Astellas Pharma Inc. market
Xtandi, a triple-acting oral antiandrogen receptor, to treat
castration-resistant prostate cancer.
Aragon Pharmaceuticals Inc.'s
second-generation androgen receptor antagonist, is in Phase II testing to
treat prostate cancer.
Corresponding author Charles Sawyers is a cofounder of Aragon Pharmaceuticals
and a co-inventor of both Xtandi and ARN-509 (see Rational approach to
Xtandi resistance, page 1).
Published online May 9, 2013
Two provisional patent
applications filed; licensing status undisclosed
Balbas, M.D. et al.
eLife; published online April 9, 2013;
Contact: Charles L. Sawyers, Memorial Sloan-Kettering Cancer
New York, N.Y.
Contact: Yang Shen, Toyota Technological Institute at Chicago,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]